Kasparova E A, Fedorov A A, Yang Biao
Research Institute of Eye Diseases, Moscow, Russia.
Vestn Oftalmol. 2020;136(3):64-73. doi: 10.17116/oftalma202013603164.
To evaluate the efficiency of modified crosslinking (M-CXL) in the treatment of purulent keratitis (PK) and corneal ulcers, including ulcers of mixed etiology.
M-CXL method involves simultaneous performance of CXL and frequent instillations of anti-infective agents (one drop every 5 minutes for 1 hour). The study included 39 patients (41 eyes) with purulent corneal ulcers (PCU) of various origin. The main group consisted of 26 patients (27 eyes) who were treated with M-CXL in combination with active conservative therapy. In the control group (13 patients, 14 eyes) only active conservative management was used.
Complete suppression of the purulent process in the main group was achieved in 21 (77.8%) eyes after 32.6±10.66 days, in the control group - in 9 (64.3%) eyes in 52.4±16.6 days. Complete suppression of purulent keratitis was achieved in 100% of cases with bacterial keratitis, 83% of cases with fungal keratitis and 70.5% of cases with mixed keratitis. When purulent infiltration occupied the entire depth of the stroma but was limited in area (less than 6 mm), the efficiency of M-CXL decreased to 66.6%. The clinical effect of M-CXL was absent or insufficient when PK extended to the Descemet's membrane with an area of more than 7 mm.
In 77.8% of cases, modified crosslinking has showed pronounced therapeutic effect - complete arrest of purulent corneal infiltration. Recovery time in the main group was 1.6 times shorter than in the control group (<0.05). Resorption of the purulent infiltration occupying all layers of the stroma up to the Descemet's membrane with extensive areas was not achieved, however the corneal melting and keratitis progression were stopped, which allowed planned therapeutic penetrating keratoplasty with a graft of smaller diameter to be performed.
评估改良交联术(M-CXL)治疗化脓性角膜炎(PK)和角膜溃疡(包括混合病因溃疡)的疗效。
M-CXL方法包括同时进行交联术及频繁滴注抗感染药物(每5分钟1滴,共1小时)。该研究纳入了39例(41只眼)不同病因的化脓性角膜溃疡(PCU)患者。主要组由26例(27只眼)接受M-CXL联合积极保守治疗的患者组成。对照组(13例患者,14只眼)仅采用积极保守治疗。
主要组在32.6±10.66天后,21只眼(77.8%)实现了化脓过程的完全抑制;对照组在52.4±16.6天后,9只眼(64.3%)实现了化脓过程的完全抑制。细菌性角膜炎病例中100%实现了化脓性角膜炎的完全抑制,真菌性角膜炎病例中83%实现了化脓性角膜炎的完全抑制,混合性角膜炎病例中70.5%实现了化脓性角膜炎的完全抑制。当化脓性浸润占据基质全层但面积有限(小于6mm)时,M-CXL的疗效降至66.6%。当PK扩展至Descemet膜且面积超过7mm时,M-CXL无临床效果或效果不佳。
在77.8%的病例中,改良交联术显示出显著的治疗效果——化脓性角膜浸润完全停止。主要组的恢复时间比对照组短1.6倍(<0.05)。然而,对于占据基质各层直至Descemet膜且面积广泛的化脓性浸润,未能实现吸收,但角膜溶解和角膜炎进展得以停止,这使得能够进行计划中的治疗性穿透性角膜移植术,且移植片直径较小。